Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 15/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508080 | 0.89 | ATM (0.43) | GRIN2BALDH1A1 | |
| SCHEMBL6498399 | 0.78 | KDM4E (0.52) | GRIN2BKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL6497126 | 0.77 | ATM (0.45) | GRIN2BALDH1A1 | |
| SCHEMBL6497602 | 0.69 | MEN1 (0.49) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL6499452 | 0.69 | ALDH1A1 (0.43) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL6501440 | 0.68 | ALDH1A1 (0.40) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL6501602 | 0.67 | KDM4E (0.56) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL7464598 | 0.66 | FFAR1 (0.44) | GRIN2B | |
| SCHEMBL6505225 | 0.65 | KMT2A (0.43) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL6497606 | 0.64 | KDM4E (0.54) | KDM4EMEN1ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | GRIN2B 820/4885KDM4E 945/4885MEN1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.